11-11-2013, 11:53 PM
UK-listed drug company Shire has agreed to buy the US's ViroPharma - a rare disease biopharmaceutical firm - for about $4.2bn (£2.6bn).
Shire will pay $50 for each ViroPharma share - a 27% premium on Friday's closing price.
Shire will pay $50 for each ViroPharma share - a 27% premium on Friday's closing price.